



(12) Translation of
European patent specification

(11) NO/EP 2246336 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 241/20 (2006.01)
A61K 31/4965 (2006.01)
A61P 11/00 (2006.01)
A61P 43/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.09.28
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.07.01
(86)	European Application Nr.	09714302.8
(86)	European Filing Date	2009.02.26
(87)	The European Application's Publication Date	2010.11.03
(30)	Priority	2008.02.28, JP, 2008046999
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(73)	Proprietor	Nippon Shinyaku Co., Ltd., 14, Kisshoin Nishinosho Monguchicho Minami-ku, Kyoto-shiKyoto 601-8550, Japan
(72)	Inventor	MURAKAMI, Koji, 2-2A Nippon Shinyaku Yamashina-shataku39 Oyake SakanotsujichoYamashina-ku, Kyoto-shiKyoto 607-8182, Japan TORAMOTO, Takuya, Nippon Shinyaku Nagaoka-ryo1-8-17 Kaiden, Nagaokakyo- shiKyoto 617-0826, Japan
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **FIBROSIS INHIBITOR**

(56) References
Cited:

US-A- 6 046 233, WO-A1-02/085412, WO-A2-2006/113704
WO-A2-2010/075861, WO-A2-2010/018549, EP-A1- 1 380 307
WO-A1-96/26721, WO-A1-02/088084, US-B2- 7 205 302
NAKAMURA ET AL: "Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea
prodrugs of a prostacyclin receptor agonist", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 15,
no. 24, 17 October 2007 (2007-10-17), pages 7720-7725, XP022302066, PERGAMON, GB
ISSN: 0968-0896, DOI: 10.1016/J.BMC.2007.08.052
MURAKAMI S.: 'TXA Gosei Koso Sogai Sayo o Awasemotsu Chojikan Sayogata PGI 2 Agonist
(ONO-1301) ni yoru Hai Sen'isho Chiryo Koka no Kento' THE JOURNAL OF THE JAPANESE
RESPIRATORY SOCIETY vol. 43, 2005, page 253, XP002998196

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Farmasøytisk preparat omfattende et heterocyklisk derivat valgt fra 2-{4-[N-(5,6-
difenylpyrazin-2-yl)-N-isopropylamino]butyloksy} eddiksyre og 2-{4-[N-(5,6-
5 difenylpyrazin-2-yl)-N-isopropylamino]butyloksy}-N-(metylsulfonyl)acetamid eller et
farmasøytisk akseptabelt salt derav som en aktiv bestanddel for anvendelse som en
fibroseinhibitor.

2. Farmasøytisk preparatet ifølge krav 1 for anvendelse ved behandling av en sykdom
10 valgt fra gruppen bestående av interstitiell lungebetennelse (lungefibrose),
hepatocirrose og sklerodermi.